Insights from the touchONCOLOGY Future Leaders 2025
As advances across all oncology specialties continue to evolve at pace, staying ahead of the curve is more important than ever. From gene expression profiling and liquid biopsy, to the integration of minimal residual disease monitoring using ctDNA and the potential of CAR-T therapy, innovation is reshaping the way clinicians diagnose and treat even the more difficult-to-treat cancers. With the second half of 2025 underway, we asked our touchONCOLOGY Future Leaders 2025 to share the developments they believe will shape the future of the field. Here, they highlight five exciting areas that promise to transform practice – not only as the year draws to a close, but well into the future.





The demonstration of efficacy for fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) plus durvalumab in resectable, locally-advanced gastroesophageal junction and gastric cancers, as evidenced by the MATTERHORN trial, marks a potential paradigm shift. Immune checkpoint inhibitors are increasingly being incorporated into pre- and post-operative standard-of-care regimens.
5 Key developments that have changed oncology in 2025
We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
Opening soon!

Nominations for touchONCOLOGY Future Leaders 2026
We are excited to announce that nominations for the touchONCOLOGY Future Leaders 2026 will open soon, and we invite the oncology and haematology community to share their suggestions for exceptional individuals who are shaping the future of oncology and haematology through innovation and excellence in patient care.
Register below to hear about nominations as soon as they open!
Citation: 5 exciting developments in oncology to watch in 2025 and beyond. touchONCOLOGY.com. August 26th, 2025.
Register now to receive the touchONCOLOGY newsletter!
Don’t miss out on hearing about our latest peer reviewed articles, expert opinions, conference news, podcasts and more.
